Vuong Trieu Increases Holdings in Oncotelic Therapeutics
Chairman and CEO Vuong Trieu buys 65,000 shares of Oncotelic Therapeutics.
Key Points
- Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, bought 65,000 shares on June 22, 2026, at $0.05 each.
- Oncotelic Therapeutics trades on the OTC Markets OTCQB with a market cap of about $22.2 million and a P/E ratio of 0.08.
- Recent insider transactions include multiple purchases by Vuong Trieu and CFO Amit Shah, reflecting ongoing insider interest.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Vuong Trieu, the Chairman and CEO of Oncotelic Therapeutics, Inc. (OTC Markets OTCQB: OTLC), acquired 65,000 shares of the company. The shares were purchased at $0.05 each, amounting to a $3,250 transaction. This was not part of a planned trading program.
Insider Buying and Selling at Oncotelic Therapeutics, Inc.
Recent insider activity at Oncotelic Therapeutics shows a series of purchases by its top executives. Vuong Trieu has been actively buying shares, with transactions on June 24, June 23, and June 17, 2026, totaling over 400,000 shares in recent weeks. Additionally, Amit Shah, the CFO, bought 20,000 shares on June 22, 2026, at the same price. None of these purchases were under pre-arranged trading plans, indicating a strong personal interest in the company's stock.
Oncotelic Therapeutics, Inc. Stock Up 33.3%
Shares of Oncotelic Therapeutics traded around $0.05 on Thursday. The company has a market capitalization of approximately $22.2 million. It boasts a P/E ratio of 0.08, reflecting its low earnings relative to its share price. The stock's 52-week range is between $0.02 and $0.11, with a 50-day moving average of $0.05 and a 200-day moving average of $0.07. The company's beta is -0.317, suggesting it moves inversely to the overall market.
$OTLC stock price
Daily closing prices, year to date. Not investment advice.
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Agoura Hills, California. It focuses on developing drugs for orphan oncology indications, including antisense and small molecule injectable drugs for cancer treatment. Key projects include OT-101 for pancreatic cancer and OXi4503 for acute myeloid leukemia. The company, led by CEO Dr. Vuong Trieu, employs 38 people.
Bottom Line
Vuong Trieu's recent purchase of Oncotelic Therapeutics shares highlights his confidence in the company's future. Insider buying can sometimes signal positive expectations from those with intimate knowledge of the company. However, investors should remember that these transactions are disclosed after they occur and reflect past actions, not current intentions.
Get Oncotelic Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OTLC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.